Number of pages: 100 | Report Format: PDF | Published date: March 29, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global multiplex biomarker imaging market was valued at US$ 470.1 million in 2022 and is expected to register a revenue CAGR of 5% to reach US$ 1,262.50 million by 2031.
Multiplexed imaging is a novel and intriguing approach to collecting information from human tissue samples by viewing a much larger number of biomarkers than standard microscopy. By detecting many biomarkers simultaneously, biological pathways formerly studied in isolation may now be studied in concert, and complex tissue and cell phenotypes can be discovered and investigated. Many distinct technologies for multiplexed imaging have emerged, each with a unique strategy for achieving increased complexities.
Proteomic validation is critical for new biomarker clinical uptake in breast cancer. Immunohistochemistry (IHC) detects protein expression while retaining the morphological context of tissue structures. (e.g. epithelium, stroma, blood vessels). Immunohistochemistry multiplexing, or the simultaneous detection of numerous biomarkers on a single tissue segment, can capture the interaction of proteins and complicated processes involved in tumor genesis, progression, and metastasis. It might also be used as a stand-in for identifying multigene signatures. An IHC biomarker panel that includes estrogen receptor (ER), progesterone receptor (PgR), and Her2/neu, as well as the cell proliferation marker Ki671-4, for example, may be prognostically similar to the RNA-based analytical approach Oncotype Dx.
A biomarker is described as a "defined characteristic measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions.” Oncology extensively uses imaging biomarkers (IBs) and biospecimen-derived biomarkers. Biomarkers are used in healthcare settings to screen for illness, diagnose and stage cancer, target surgical and radiation therapies, guide patient stratification, and predict and monitor therapeutic efficacy and toxicity. Biomarkers in the research guide the development of investigational drugs as they progress along the pharmacological audit trails, indicating the presence of drug targets, target inhibition, biochemical pathway modulation, or pathophysiological alteration by investigational drugs, therapeutic efficacy in specific groups of patients, and drug resistance track.
An imaging biomarker (IB) is a measurement calculated from one or more medical pictures. Many IBs are commonly utilized in healthcare imaging biomarkers (IBs). They are easily available, low-cost, non-invasive instruments for screening, tumor detection, and serial patient monitoring, including evaluations of response to therapy and identification of therapeutic problems. IBs can follow a specific tumor over time, map the geographic heterogeneity within tumors, and analyze numerous distinct lesions separately within an individual.
The globally rising frequency of cancer and tumors and the urging need for more effective medications and therapies for various cancers are driving the global multiplex biomarker imaging market revenue growth. Additionally, the growing need for multiplex biomarker imaging approaches for obtaining detailed information about tumor anatomy promotes market revenue expansion. Furthermore, increased knowledge of the benefits of multiplex biomarker imaging technologies, such as the examination of hundreds of tissues in a single turn for accurate information and cost-effectiveness, has an impact on the market. Furthermore, increased investment in cancer diagnostics by commercial and non-profit organizations, technical improvement, and an increasing number of end-users provide profitable prospects to market participants during the forecast period.
The growing popularity of multiplex biomarker imaging techniques originates from the desire to overcome the constraints of traditional approaches, such as flow cytometry and serial methods, by delivering more comprehensive information on the full tumor anatomy. In the face of continual changes in tissue shape, the requirement for contextual evaluation of the tissue microenvironment is a significant element driving the demand for multiplex biomarker imaging. The demand for these technologies is rising due to their role in creating more effective medications. Multiplex biomarker imaging is widely utilized worldwide to improve knowledge of cancer biology and expose the complexity of various biological systems.
The global multiplex biomarker imaging market has been analyzed from four perspectives: component type, imaging techniques, application, end user, and region.
Multiplex Biomarker Imaging Market by Component Type
Based on component type, the global multiplex biomarker imaging market has been segmented into instruments, software, and services.
The instruments segment is expected to capture the largest market revenue share during the forecast period. However, the software segment is expected to grow fastest during the forecast period as more automated software packages are becoming accessible to researchers. These software modules aid in investigating various diseases and enhance the quantitative analytical workflow.
Multiplex Biomarker Imaging Market by Imaging Techniques
Based on imaging techniques, the global multiplex biomarker imaging market has been segmented into immunohistochemistry assay, fluorescent in-situ hybridization assay, and tissue microarray.
The immunohistochemistry assay segment dominates the global multiplex biomarker imaging market. Multiplex immunohistochemistry assay biomarker imaging is a technique for identifying and quantifying the expression of particular proteins in tissue samples. This technique may be used to investigate the impact of medications or illnesses on the tissues, as well as to identify disorders. The IHC method has several advantages over traditional staining techniques, including the ability to use it on formalin-fixed, frozen, or preserved tissues, the lack of the need for special fixation procedures prior to embedding, and the ability to preserve samples for long periods of time without compromising their structural integrity.
Multiplex Biomarker Imaging Market by Application
Based on application, the global multiplex biomarker imaging market has been segmented into research and clinical diagnostics.
The research segment is expected to dominate the market during the forecast period. Quantitative biomarkers that have crossed the first translational gap and are being used to test hypotheses in research studies and clinical trials include vascular parameters such as initial region under the gadolinium curve (iAUGC) or transfer constant (Ktrans) from dynamic gadolinium enhanced (DCE) contrast imaging and apparent diffusion coefficient (ADC) from diffusion weighted MRI. Apparent diffusion coefficient has been studied as a response biomarker in a variety of tumor types and therapy in research studies, including multicenter trials. These investigations have revealed a consistent pattern of increasing ADCmean to variable degrees with different treatments.
Multiplex Biomarker Imaging Market by End User
Based on end users, the global multiplex biomarker imaging market has been segmented into translational laboratories, biopharmaceutical companies, and academic institutes.
The biopharmaceuticals company segment is expected to dominate the global market in terms of revenue share during the forecast period. This was mostly owing to an increase in demand from drug companies and research institutions throughout the world for high-quality proteins for medication development and other uses. IHC assays have been prevalent during the forecast period due to their ability to detect low levels of protein expression with high specificity and sensitivity at lower costs when compared to other detection techniques, such as western blotting or gel extraction.
Multiplex Biomarker Imaging Market by Region
Based on region, the global multiplex biomarker imaging market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
During the forecast period, North America is expected to be the prominent region in the multiplex biomarker imaging market. Favorable government policies encouraging the use of novel and sophisticated biomarkers, as well as expansion in healthcare infrastructure and research grants from the government and ruling authorities, are projected to drive market revenue growth in this area. Europe is the second most important market, followed by Asia Pacific.
The enormous healthcare industry in the Asia Pacific area, particularly in India, China, and Japan, is a crucial propelling driver for the growth of the multiplex biomarker imaging market in this region. As a result, Asia Pacific is expected to develop at a rapid revenue CAGR during the forecast period, whilst Latin America is expected to grow at a slow to moderate rate.
The Middle East and Africa region is expected to expand at a low to moderate rate due to low per capita income, which leads to a lack of access to multiplex biomarker imaging. Latin America is another significant area experiencing moderate expansion in the multiplex biomarker imaging market.
The fact that industry participants are increasingly focused on developing new biomarker approaches for cancer research is also helping to drive acceptance. Flagship Biosciences Inc.'s cTA platform and decision support approach for tissue biomarkers was demonstrated at the American Association for Cancer Research (AACR) Annual Meeting in April 2018. The platform employs computational analysis to offer quantitative, contextual data on tumor tissue, which aids in clinical trial decision-making. Its technical team has also revealed significant advances in immune cell profiling and tumor cell analysis. Pharmaceutical businesses all across the world can use the multiplexed biomarker platform to expedite their drug development efforts. Some of the key players in the multiplex biomarker imaging market include,
The instruments segment leads the global multiplex biomarker imaging market in terms of the largest revenue share.
Multiplexed imaging is a novel and intriguing approach to collect information from human tissue samples by viewing a much larger number of biomarkers than standard microscopy.
The estimated market size of the global multiplex biomarker imaging industry in 2031 will be US$ 1,262.50 million.
The expected revenue CAGR of the global multiplex biomarker imaging market during the forecast period will be 11.6%.
The Asia Pacific is the key growth region in the global multiplex biomarker imaging market.
*Insights on financial performance are subject to the availability of information in the public domain